0001376474-26-000247.txt : 20260324
0001376474-26-000247.hdr.sgml : 20260324
20260324155508
ACCESSION NUMBER: 0001376474-26-000247
CONFORMED SUBMISSION TYPE: D/A
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering
FILED AS OF DATE: 20260324
DATE AS OF CHANGE: 20260324
EFFECTIVENESS DATE: 20260324
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Porosome Therapeutics, Inc.
CENTRAL INDEX KEY: 0001934919
ORGANIZATION NAME:
EIN: 873482047
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D/A
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-492097
FILM NUMBER: 26785983
BUSINESS ADDRESS:
STREET 1: ONE BOSTON PLACE, STE 2631
CITY: BOSTON
STATE: MA
ZIP: 02108
BUSINESS PHONE: 781 956 9799
MAIL ADDRESS:
STREET 1: ONE BOSTON PLACE, STE 2631
CITY: BOSTON
STATE: MA
ZIP: 02108
FORMER COMPANY:
FORMER CONFORMED NAME: Viron Therapeutics Holdings, Inc.
DATE OF NAME CHANGE: 20220622
D/A
1
primary_doc.xml
X0708
D/A
LIVE
0001934919
Porosome Therapeutics, Inc.
ONE BOSTON PLACE, STE 2631
BOSTON
MA
MASSACHUSETTS
02108
781 956 9799
DELAWARE
Viron Therapeutics Holdings, Inc.
Corporation
true
2021
Guillermo
Marmol
One Boston Place
Suite 2631
Boston
MA
MASSACHUSETTS
02108
Executive Officer
Biotechnology
No Revenues
- 06b
true
0001376474-25-000506
2023-09-08
false
true
false
50000
Indefinite
3625000
Indefinite
false
7
0
0
0
The Chief Executive Officer, Guillermo Marmol, receives no compensation from the proceeds.
false
Porosome Therapeutics, Inc.
/s/ Guillermo Marmol
Guillermo Marmol
Chief Executive Officer
2026-03-20